Influence of the dynamics of body weight on the risk factors of cardiovascular disease in patients with type 2 diabetes during the first year of insulin treatment

The aim of the present study was to investigate whether insulin treatment-induced weight gain had an adverse impact on cardiovascular risk factors in insulin-treated type 2 diabetic patients during the first year after initiating insulin therapy when insulin analogues or human insulins are used. A total of 157 patients with newly insulinized type 2 diabetes were included in the study. The patients were divided in two groups. First group consisted of subjects (mean age 57 [45; 73], duration of diabetes of 10 years [4; 16]) who had received long-acting basal (glargine, detemir), premixed (biphasic insulin aspart 30, Humalog Mix 25) or short-acting (aspart, lispro) insulin analogues. Patients from second group (mean age 59 [46; 75], duration of diabetes of 10 years [5; 15]) were treated with intermediate-acting basal (Protophane, Humulin NPH insulin), premixed (biphasic human insulin 30, Humulin M3) and regular (Actrapid, Humulin R) human insulins. Our study has shown that insulin-induced weight gain may not adversely affect cardiovascular risk factors, particularly, lipid profile, in insulin-treated type 2 diabetic patients during the first year after initiating insulin therapy. Use of insulin analogues for treatment of type 2 diabetes patients results in better glycaemic control, significant declines in blood lipid concentrations, less increase in waist circumference compared with human insulins during the first year after initiating insulin therapy.

type 2 diabetes, insulin analogues, weight gain, blood lipids

1. American Diabetes Association. Standards of medical care of diabetes. Diabetes Care. 2009;32(1):13–S61.

2. Anderson JV, Kendall CV, Jenkins DJ. Importance of weight management in type 2 diabetes: review with meta-analyses of clinical studies. J Am CollNutr. 2003;22:331–339.

3. Bagg W, Plank LD, Gamble G, Drury PL, Sharpe N, Braatvedt GD. The effects of intensive glycaemic control on body composition in patients with type 2 diabetes. Diabetes, Obes and Metab. 2001;3:410–416.

4. Fagot-Campagna A, Rolka DB, Beckles JB, Greg EW, Narayan KM. Prevalence of lipid abnormalities, awareness, and treatment in US adults with diabetes. Diabetes. 2000;49 (Suppl. 1):78–86.

5. Hartman I. Insulin Analogues: Impact on treatment success, satisfaction, quality of life and adherence. Clinical Medicine and Research. 2008;6:54–67.

6. Henry RR, Gumbiner B, Ditzler T, Wallace P, Lyon R, Glauber HS. Intensive conventional insulin therapy for type 2 diabetes: metabolic effects during a 6-month outpatient trial. Diabetes Care. 1993;16:21–31.

7. Knowler WC, Pettitt DJ, Savage RJ. Diabetes incidence in Pima Indians: contributions of obesity and parental diabetes. Am J Epidemiol. 1981;113:144–156.

8. Larger E, Rufat P, Dubois-Laforgue D, Ledoux S. Insulin and weight gain: myth or reality? Diabetes Metab. 2001;27:23–27.

9. Larger E. Weight gain and insulin treatment. Diabetes Metab. 2005. Sep;31:4851–4856.

10. Makkimattila S, Nikkila K, Yki-Jarvinen H. Causes of weight gain during insulin therapy with and without metformin in patients with type 11 diabetes mellitus. Diabetologia. 1999;42:406–412.

11. Malmberg K. Prospective randomized study of intensive insulin treatment on long-term survival after acute myocardial infarction in patients with diabetes mellitus. BMJ. 1997;314:1512–1515.

12. Nathan D M, Buse J B, Davidson MB, Heine RJ, Holman RR, Sherwin R, Zinman B. Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy. Diabetes Care. 2006;29:1963–1972.

13. Raz I, Wilson PW, Strojek K. et al. Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial. Diabetes Care. 2009;32:281–386.

14. Rigalleau V, Delafaye C, Baillet L. Composition of insulin-induced body weight gain in diabetic patients: a bio-impendance study. Diabetes Metab. 1999;25:321–328.

15. Robert R. Henry. Preventing cardiovascular complications of type 2 diabetes: focus on lipid management. Clinical Diabetes. 2001;19 (3):113–201.

16. Sinha A, Fomica C, Tsalamandris C. et al. Effects of insulin on body composition in patients with insulin-dependent and non-insulin-dependent diabetes mellitus. Diabetic Med. 1996;13:40–46.

17. UK Prospective Diabetes Study (UKPDS) Group: Intensive blood- glucose control with sulfonylureas or insulin compared to conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–853.

18. Wolffenbuttel BH, Leurs BP, Sels JP et al. Improved blood glucose control by insulin in type 2 diabetic patients has no effect on lipoprotein (a) levels. Diabetic Med. 1993;10:427–430.